Bristol-Myers Squibb Compnay

Zymogenetics, Inc.

Susan H Julien

Paul O Sheppard

Mohan Srinivasan

Brigitte Devaux

Mark F Maurer

Indrani Chakraborty

Daniel F Ardourel

Tseng-hui Timothy Chen

Hong Yan Liu

Chung-Leung Chan

Brian J Reardon

Tseng-Hui Timothy Chen

The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

Antibodies to TIGIT

The expression vectors and methods using anexpression system for the large scale production of FGF18 are described. The vectors utilize the FGF18 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in. Using the expression vectors, the FGF18 gene was produced into a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficientstrains, as well as OmpT and fhuA negative strains transformed with an FGF18 expression vector.

FGF18 production in prokaryotic hosts

Growing community of inventors

Seattle, WA, United States of America

Susan H Julien